574 articles
A landmark Phase 3 trial evaluates whether omecamtiv mecarbil, a cardiac myosin activator, reduces cardiovascular death in HFrEF patients.
A Phase 4 real-world study comparing extended-release methylphenidate formulations for ADHD was terminated before yielding conclusions.
A phase 3 trial adding ERN/LRPT to statin therapy for dyslipidemia was terminated early, raising questions about the drug's clinical future.
NIDCR researchers compared stromal cells from bone marrow, skin, spleen, and fat to identify which best regenerates bone and supports blood formation.
A 10-week supervised strength program targets chronic inflammation and self-efficacy in long-term allogeneic HCT survivors.
A terminated RCT explored whether immunotype-targeted supplements could reduce iAge®, an AI-derived biomarker of chronic inflammation and immune aging.
A phase II trial tests whether sunitinib retains activity in metastatic renal cell carcinoma after first-line immunotherapy resistance.
A Phase 1 trial examines if the triple-agonist GLP-1 drug retatrutide changes how the body processes the beta-blocker metoprolol.
A completed RCT tests whether 6 months of moderate aerobic exercise protects memory and brain structure in older adults at genetic risk for Alzheimer's.
A Phase 3 trial evaluates a next-generation quadrivalent influenza vaccine against existing options, testing both immune response and manufacturing consistency.
A completed trial finds Mat Pilates training may reduce arterial stiffness and improve vascular function in obese premenopausal women.
A first-in-human Phase 1 trial evaluates PF-07257876, a dual-checkpoint bispecific antibody targeting both CD47 and PD-L1, in hard-to-treat cancers.
